Literature DB >> 17156834

Effects of menstrual cycle phase on the reinforcing effects of phencyclidine (PCP) in rhesus monkeys.

Jennifer L Newman1, Joseph J Thorne, David K Batulis, Marilyn E Carroll.   

Abstract

Substantive evidence indicates that there are sex differences in the reinforcing effects of drugs, and gonadal steroid hormones, such as estrogen and progesterone, likely contribute to these differences. Among females, subjective effects of drugs differ as a function of menstrual cycle phase. The purpose of the present study was to compare oral self-administration of phencyclidine (PCP) in female rhesus monkeys (Macaca mulatta) across different phases of the menstrual cycle. Since the 28-day menstrual cycle of non-human primates is similar to that of humans, this model could provide important evidence supporting the implication that changes in the levels of gonadal hormones across menstrual phase can alter a drug's reinforcing effects. Oral self-administration of several concentrations of PCP (0.125, 0.25, and 0.5 mg/ml) was examined in three sexually mature female monkeys during 3-h experimental sessions. Menstrual cycle phase was determined by onset of menses and verified by examining vaginal cytology. PCP self-administration was greater during the luteal phase at the 0.125 and 0.25 mg/ml concentrations, which is normally characterized by high levels of progesterone and moderate levels of estrogen, than during the follicular phase, when levels of estrogen are increasing and progesterone levels are low. When examined within each phase, numbers of PCP deliveries were highest during the mid-luteal phase, compared to the early and mid-follicular phases. No differences in self-administration were observed between early and mid-follicular phases, but a significant difference in PCP deliveries was found between mid- and late luteal phases at the lowest concentration of PCP tested. The results from this study suggest that PCP's reinforcing effects in female monkeys differ as a function of menstrual cycle phase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17156834      PMCID: PMC1899531          DOI: 10.1016/j.pbb.2006.10.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  68 in total

Review 1.  Estrogen actions throughout the brain.

Authors:  Bruce McEwen
Journal:  Recent Prog Horm Res       Date:  2002

2.  Retrospective study: influence of menstrual cycle on cue-induced cigarette craving.

Authors:  Teresa R Franklin; Kimberly Napier; Ronald Ehrman; Peter Gariti; Charles P O'Brien; Anna Rose Childress
Journal:  Nicotine Tob Res       Date:  2004-02       Impact factor: 4.244

3.  Effects of progesterone treatment on smoked cocaine response in women.

Authors:  Mehmet Sofuoglu; David A Babb; Dorothy K Hatsukami
Journal:  Pharmacol Biochem Behav       Date:  2002-05       Impact factor: 3.533

Review 4.  Biological basis of sex differences in drug abuse: preclinical and clinical studies.

Authors:  Wendy J Lynch; Megan E Roth; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2002-09-05       Impact factor: 4.530

5.  The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women.

Authors:  Suzette M Evans; Margaret Haney; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2001-11-21       Impact factor: 4.530

6.  Effects of a non-drug reinforcer, saccharin, on oral self-administration of phencyclidine in male and female rhesus monkeys.

Authors:  Kelly P Cosgrove; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2003-07-01       Impact factor: 4.530

7.  Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder.

Authors:  Sigrid Nyberg; Göran Wahlström; Torbjörn Bäckström; Inger Sundström Poromaa
Journal:  Psychoneuroendocrinology       Date:  2004-07       Impact factor: 4.905

8.  Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase.

Authors:  Tara L White; Angela J H Justice; Harriet de Wit
Journal:  Pharmacol Biochem Behav       Date:  2002-11       Impact factor: 3.533

9.  Biological basis of sex differences in the propensity to self-administer cocaine.

Authors:  Ming Hu; Hans S Crombag; Terry E Robinson; Jill B Becker
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

10.  Allopregnanolone increase in striatal N-methyl-D-aspartic acid evoked [3H]dopamine release is estrogen and progesterone dependent.

Authors:  Ricardo J Cabrera; Claudia Bregonzio; Myriam Laconi; Alejandra Mampel
Journal:  Cell Mol Neurobiol       Date:  2002-08       Impact factor: 5.046

View more
  5 in total

Review 1.  The role of progestins in the behavioral effects of cocaine and other drugs of abuse: human and animal research.

Authors:  Justin J Anker; Marilyn E Carroll
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

2.  Examining the reinforcement-enhancement effects of phencyclidine and its interactions with nicotine on lever-pressing for a visual stimulus.

Authors:  Natashia Swalve; Scott T Barrett; Rick A Bevins; Ming Li
Journal:  Behav Brain Res       Date:  2015-05-27       Impact factor: 3.332

3.  The effects of social contact on cocaine intake in female rats.

Authors:  Andrea M Robinson; Gaylen E Fronk; Huailin Zhang; Scott Tonidandel; Mark A Smith
Journal:  Drug Alcohol Depend       Date:  2017-05-24       Impact factor: 4.492

4.  Increased impulsive choice for saccharin during PCP withdrawal in female monkeys: influence of menstrual cycle phase.

Authors:  Marilyn E Carroll; Emily A Kohl; Krista M Johnson; Rachel M LaNasa
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

5.  Sex and menstrual cycle effects on chronic oral cocaine self-administration in rhesus monkeys: Effects of a nondrug alternative reward.

Authors:  Marilyn E Carroll; Molly Collins; Emily A Kohl; Seth Johnson; Ben Dougen
Journal:  Psychopharmacology (Berl)       Date:  2016-06-18       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.